Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Dose Adjustment Considerations in Patients With Chronic Kidney Disease: Dr Linda Awdishu
November 3rd 2023For patients with chronic kidney disease, dose adjustments for other medications requires coordination with other specialists to maintain treatment efficacy, explained Linda Awdishu, PharmD, FASN, professor and division head of clinical pharmacy at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences.
Read More
Dr Laura Denby: Long Noncoding RNA Is a Good Biomarker for Acute Kidney Injury
November 3rd 2023Smaller noncoding RNA is being used in clinical practice and as knowledge grows of long noncoding RNA, use of it should follow, explained Laura Denby, PhD, Kidney Research UK Senior Fellow, senior lecturer and principal investigator in the Centre for Cardiovascular Science at the University of Edinburgh.
Read More
Amivantamab Plus Lazertinib Improved PFS for EGFR-Mutated Advanced NSCLC
October 23rd 2023MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy after progression on osimertinib.
Read More
Trastuzumab Deruxtecan Demonstrates Efficacy Reducing Brain Metastases in HER2m NSCLC
October 22nd 2023Regardless of presence of brain metastases, patients with HER2-mutant (HER2m) non–small cell lung cancer (NSCLC) showed systemic responses to trastuzumab deruxtecan. In addition, the therapy showed intracranial efficacy to reduce the size of brain metastases.
Read More
Adding Adjuvant Nivolumab Builds on Standard of Care for Resectable NSCLC
October 22nd 2023The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting and may have practice-changing implications.
Read More
Overcoming the Efficacy-Effectiveness Gap in Cancer Therapy Research
October 21st 2023With stringent criteria, randomized controlled trials are the cornerstone of cancer intervention research, but the result is they do not represent the majority of patients, which leads to a gap between the efficacy seen in trials and the effectiveness in the real-world setting.
Read More
Christine Pfaff on Ensuring Patient Access to Affordable Treatments
October 17th 2023To ensure patients are getting timely access to their treatments, there needs to be better collaboration between payers and providers, said Christine Pfaff, RPh, senior regional director of operations, American Oncology Network.
Read More
FDA Grants Pembrolizumab Sixth Indication in NSCLC
October 17th 2023The anti–PD-1 agent pembrolizumab was granted a new indication to treat patients with resectable non–small cell lung cancer (NSCLC) as a neoadjuvant treatment with chemotherapy and continued as adjuvant treatment after surgery.
Read More
Patient, Provider Education and Payer Management Can Improve Biosimilar Uptake: Dr Bincy Abraham
October 15th 2023Biosimilars are becoming more common as more launch on the market in the United States, but patient and provider education can help speed uptake of these products, explained Bincy Abraham, MD, Houston Methodist – Weill Cornell.
Read More
Novel Approaches to Head and Neck Cancer at Vanderbilt Ingram Cancer Center
October 12th 2023Speakers at an Institute for Value-Based Medicine event with Vanderbilt University Medical Center highlighted the novel therapies and techniques being used to improve outcomes for patients with head and neck cancer.
Read More
Updates Are Driving the Field of MDS Forward, but Changes Still Needed
September 25th 2023In just the last 2 years there have been updates in classification, risk assessment, and response criteria in myelodysplastic syndromes (MDS), but additional efforts are needed to improve these, and there remains a need for better therapies.
Read More
Biosimilars Had a Huge Impact on Total Cost of Care, Says AON’s Christine Pfaff
September 23rd 2023In a few short years, biosimilars have driven down total cost of care in oncology through providing competition for expensive drugs, explained Christine Pfaff, RPh, senior regional director of operations, American Oncology Network (AON).
Read More
Study Highlights Association of COPD and CVDs, Need for Prevention and Management
September 22nd 2023Among adults 40 years and older with chronic obstructive pulmonary disease (COPD), there is a higher prevalence of cardiovascular diseases (CVDs) compared with a general population without COPD.
Read More